Company Overview - Dongfang Ocean (SZ 002086) announced that its wholly-owned subsidiary, Aiveke Biotechnology, has received registration approval from the Shandong Provincial Drug Administration for its procalcitonin (PCT) testing kit, which is now a registered medical device [1] - As of the latest report, Dongfang Ocean has a market capitalization of 4.7 billion yuan [1] Revenue Composition - For the first half of 2025, Dongfang Ocean's revenue composition is as follows: - Aquaculture processing accounts for 73.14% - In-vitro diagnostics account for 10.19% - Marine aquaculture accounts for 9.97% - Other businesses, including leasing and others, account for 6.7% [1]